Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.
about
Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection ModelIn vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.Meta-analysis of colistin for the treatment of Acinetobacter baumannii infectionOptimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaParadoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiClinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.Synergistic combinations of polymyxins.Pharmacotherapy for hospital-acquired pneumonia.Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date.Epidemiology of multidrug-resistant Acinetobacter baumannii strains in Iran: a systematic review and meta-analysis.Rifabutin: where do we stand in 2016?Colistin: still a lifesaver for the 21st century?Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Recent advances and perspectives in the design and development of polymyxins.Synergistic Effect of Colistin and Rifampin Against Multidrug Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis.In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques.Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers.In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates.In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase.Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii.In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens.Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study.Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing Klebsiella pneumoniae in an In Vitro Pharmacokinetic/Pharmacodynamic Model.Insight into : pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities
P2860
Q28550341-A0B5D7C4-C84C-4393-9112-B4A785EF8582Q36064268-0133532A-507F-4ACA-852E-ABD29737F964Q36310173-A05B3E5C-4EC2-4A8A-BC55-2E151E0A7CBCQ36363261-463A45EF-D719-4C3F-831A-72AEEC3F91F3Q37023206-36CC0F07-0C5D-408C-9774-179EA5159FE5Q37023227-087F4E29-38B1-479A-ABB0-A27940C8FDF2Q37469403-0141A647-8C7B-414F-83E0-FA1A3F9C9625Q37562099-D47FAE61-1855-4412-BEC8-232CD8BB88F5Q37586960-B1F05643-5C20-4564-B14A-D919426B60F0Q38192023-A5EECDFA-930A-46B8-BE10-DB928A90BE3FQ38197844-C7DE2882-0AA3-495F-AD1E-B18D06AD31E4Q38232199-F835A418-7282-4BFD-9F4F-8DDE9DB67196Q38722054-E0642DCD-2058-4F83-89DB-43E9382CA004Q38786540-DE517531-43D6-4612-880D-866ABADB599DQ38940249-EEF86715-919A-4D10-A6F9-F8A308DDEEC3Q39143298-B4761E0D-EDA0-4265-B3EF-DA9CBB30A3D5Q39170967-7336921E-DAF5-41C1-AB4F-FA73527923AFQ39190865-83261B88-94CB-4CB3-A277-E4BD9ABD6401Q39335729-280238A0-1D89-467B-8357-7D2F9D32DD44Q40179477-0E4548CE-ECA4-4A19-8F68-59D4B5010890Q40441668-C62849C5-7F24-4006-890F-23422ED09EE5Q40485776-BD3F6927-3552-4CD5-AC47-DC7A8286AFA3Q40855475-07E1428C-1C2E-44E7-908A-28A1432681DFQ41228310-7FE099A8-6E61-41B6-8085-678ABCD4571FQ41736250-1510F92B-D24A-44D2-844E-0AE2811BDAECQ41833657-E679E91D-6B76-49B7-870E-FC16209D7DD7Q52715802-2DC1C04B-71CC-46E5-A6C9-23CF9618491EQ53689690-6E16EA38-C1FF-4E2D-8A25-7C70DB35D2C3Q55340900-610D14CD-3532-44A3-BBC9-DD54D2F21A0BQ57168270-D06B15D9-79EC-4BC3-AB81-B63810B4656A
P2860
Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@en
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@nl
type
label
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@en
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@nl
prefLabel
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@en
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@nl
P2093
P2860
P356
P1476
Synergistic activity of colist ...... kinetic/pharmacodynamic model.
@en
P2093
Alan Forrest
Brian Tsuji
Hee Ji Lee
Jurgen B Bulitta
Phillip J Bergen
P2860
P304
P356
10.1128/AAC.00703-13
P407
P577
2013-05-28T00:00:00Z